Application no. and date | 08732695.5 (espacenet) (Federated) (European Patent Register), 20080321 | Patent/reg. no. and date | DK/EP 2139494, 20200311 | Publication date | 20100106 | Priority no. and date | US 896286 P, 20070322 | EP pub. no. and date |
EP 2139494 20100106 | Effective date | | Applicant/owner | AstraZeneca AB,
151 85 Södertälje, SE | Applicant ref. no. | 1529536 | Inventor | BINDRA, Dilbir, S., 1 Squibb Drive
New Brunswick, NJ 08903, US, DALI, Mandar, V., 1 Squibb Drive
New Brunswick, NJ 08903, US, PARAB, Prakash, V., 1 Squibb Drive
New Brunswick, NJ 08903, US, PATEL, Jatin, M., 1 Squibb Drive
New Brunswick, NJ 08903, US, TAO, Li, 1 Squibb Drive
New Brunswick, NJ 08903, US, TEJWANI, Ravindra, W., 1 Squibb Drive
New Brunswick, NJ 08903, US, VATSARAJ, Nipa, 1 Squibb Drive
New Brunswick, NJ 08903, US, WU, Yongmei, 1 Squibb Drive
New Brunswick, NJ 08903, US | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB
, GB | Opponent | | IPC Class | A61K 31/70 (2006.01) , A61K 9/16 (2006.01) , A61K 9/20 (2006.01) , A61P 3/10 (2006.01) | Title | FARMACEUTISKE FORMULERINGER, DER INDEHOLDER DAPAGLIFLOZIN-PROPYLENGLYCOLHYDRAT | Int. application no. | US2008057888 | Int. publication no. | WO2008116179 | Related patent (certificate) | CA 2020 00035 | Status | DK/EP patent | Pædiatrisk forlængelse | - | Udløbsdato for pædiatrisk forlængelse | - |
|